4/28/2023 0 Comments Netspot neuroendocrineAs such, it enables your doctors to develop a precise treatment plan personalized to your particular needs. Theragnostic care is precision medicine that helps to show the biology behind each type of cancer and how it responds to certain treatments. Combining the diagnostic component with therapy is known as using “paired radiopharmaceuticals.” Your nuclear medicine specialist has special training and will discuss with you the risks and benefits of treatment.Īdditionally, the diagnostic technique may be used again after the targeted therapy is delivered to see how you and your body respond to treatment. 68 Ga DOTA-octreotate (GaTate) PET/CT is rapidly emerging as the new imaging standard of reference for neuroendocrine tumors, with greater accuracy than conventional imaging modalities and the ability to help characterize disease entities, especially when used in combination with FDG PET/CT. These therapies are referred to as “radiopharmaceuticals” because they contain limited amounts of radioactive materials. Phase 2: The doctor uses this same molecular probe to deliver targeted therapies to treat the cancer while preserving healthy tissue around it. (The probe is sometimes called a “molecular probe” because it looks for a specific kind of molecule). This scan helps accurately locate and characterize tumors in adult patients with somatostatin-receptor positive Neuroendocrine Tumors (NETs). High-grade (G3) poorly differentiated neuroendocrine carcinomas (NECs) are. Phase 1: To locate cancer, a doctor specially trained in theragnostic care uses leading-edge molecular probes and diagnostic imaging equipment to precisely locate and define areas of disease. NETSPOT is the first Gallium-68 injection, a radioactive diagnostic agent for PET/CT imaging. 68Ga-DOTATATE (NETSPOT Advanced Accelerator Applications) is currently. Determination of the Krenning score requires comparison to the liver and spleen (or kidney if not applicable). The theragnostic care process has two phases: Initially designed for assessment of 111 In-DTPA on planar imaging, the Krenning score is applicable to SPECT or PET-CT using various radiopharmaceuticals. A combination of “therapy” and “diagnostics,” this innovative approach can help treat patients with a range of conditions, including thyroid cancer, prostate cancer that has spread to bone, hyperthyroidism, and neuroendocrine tumors (NET). At Stanford Health Care, the Nuclear Medicine and Molecular Imaging team is helping to lead the development and growing use of theragnostic care.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |